A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Inclusion Criteria:

• Have Type 2 Diabetes

• Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol), as determined by the centrallaboratory at screening.

• Have been on stable diabetes treatment with metformin ≥1500 milligram (mg)/dayduring the 90 days prior to screening and maintained through randomization.

• Are of stable body weight (±5%) for at least 90 days prior to screening and agree tonot initiate an intensive diet or exercise program during the study with the intentof reducing body weight, other than the lifestyle and/or dietary measures fordiabetes treatment

Exclusion Criteria:

• Have Type 1 Diabetes

• Are currently receiving or planning to receive treatment for diabetic retinopathyand/or macular edema, for example, laser photocoagulation or intravitreal injectionsof anti-vascular endothelial growth factor inhibitors.

• Have a history of ketoacidosis or hyperosmolar state or coma within the last 6months prior to screening, or between screening and randomization.

• Have a New York Heart Association functional classification IV congestive heartfailure.

• Have an estimated glomerular filtration rate (eGFR) <45 milliliter/minute (mL/min)/1.73 square meter (m²) or lower than the country-specific threshold fordiscontinuing metformin therapy per local label as determined by the centrallaboratory at screening.

• Have a serum calcitonin level of ≥35 nanogram/Liter (ng/L), as determined by thecentral laboratory at screening.

• Have a history of an active or untreated malignancy or are in remission from aclinically significant malignancy for less than 5 years.